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Porphyrias are relatively uncommon inherited or acquired disorders in which clinical
manifestations are attributable to a disturbance of heme synthesis (porphyrin metabolism),
usually in association with endogenous or exogenous stressors. Porphyrias are characterized by
elevations of heme precursors in blood, urine, and/or stool. A number of chemicals, particularly
metals and halogenated hydrocarbons, induce disturbances of heme synthesis in experimental
animals. Certain chemicals have also been linked to porphyria or porphyrinuria in humans,
generally involving chronic industrial exposures or environmental exposures much higher than
those usually encountered. A noteworthy example is the Turkish epidemic of porphyria cutanea
tarda produced by accidental ingestion of wheat treated with the fungicide hexachlorobenzene.
Measurements of excreted heme precursors have the potential to serve as biological markers for
harmful but preclinical effects of certain chemical exposures; this potential warrants further
research and applied field studies. It has been hypothesized that several otherwise unexplained
chemical-associated illnesses, such as multiple chemical sensitivity syndrome, may represent
mild chronic cases of porphyria or other acquired abnormalities in heme synthesis. This review
concludes that, although it is reasonable to consider such hypotheses, there is currently no
convincing evidence that these illnesses are mediated by a disturbance of heme synthesis; it is
premature or unfounded to base clinical management on such explanations unless laboratory
data are diagnostic for porphyria. This review discusses the limitations of laboratory measures of
heme synthesis, and diagnostic guidelines are provided to assist in evaluating the symptomatic
individual suspected of having a porphyria. Environ Health Perspect 105(Suppl 11:37-53 (1997)
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Introduction
Porphyrias are inherited or acquired
metabolic disorders in which the clinical
manifestations are attributable to char-
acteristic patterns of overproduction of
specific heme precursors and their accumu-
lation in certain tissues as a consequence of
decreased activity ofa specific enzyme(s) in
the heme synthesis pathway, usually in
association with stimulation of the initial
stage ofthe heme-forming system by endo-
genous or exogenous stressors. When clini-
cally active, and in some cases even when
latent or in clinical remission, porphyrias
induce high levels of heme precursors in
blood, urine, and/or stool.
Porphyrias are relatively uncommon
conditions but are probably underrecog-
nized. The prevalence ofgenetic predispo-
sition to porphyria probably has been
underestimated in the general population
because ofthe limited availability ofclinical
tests for specific heme-synthesis enzymes
and because prevalence studies generally
have focused more on family members of
affected individuals and less on the general
population. The symptomatic manifesta-
tions ofporphyria, particularly the noncuta-
neous manifestations, are often nonspecific
and may not be accompanied by supporting
physical signs. Most clinicians encounter
and recognize few ifany cases ofporphyria
in the course of their careers, and in gen-
eral their levels ofsuspicion for these con-
ditions are low; yet diagnosis ofporphyria
is critically dependent on the clinician first
suspecting it as a possible cause ofa patient's
symptoms and then ordering the specific
essential diagnostic tests.
Some ofthe inherited porphyrias occur
commonly as toxicogenetic conditions,
where the genetically acquired trait is clini-
cally latent until clinical manifestations of
porphyria are triggered idiosyncratically by
exposure to certain therapeutic drugs, chem-
icals, or alcohol. Porphyria also can occur
as an acquired toxin-induced condition,
where biochemical and clinical manifesta-
tions of the porphyria are actually caused
by exposure to certain chemicals in indi-
viduals with no evident genetic predisposi-
tion. In addition, certain chemicals can
produce disturbances of heme synthesis
that are associated with alterations of
subcellular structure and functions and
characteristic changes in patterns ofheme-
precursor excretion. These measurable
changes offer potential biological markers
for detecting harmful effects of specific
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chemical exposures while their biological
effects are still preclinical and potentially
reversible. Most clinicians, however,
including specialists in occupational and
environmental medicine, are relatively
uninformed about these phenomena.
It has recently been proposed that a
variety ofchemical-associated illnesses for
which there are no widely accepted specific
diagnostic tests or etiologic explanations-
such as multiple chemical sensitivity
(MCS) syndrome, Persian GulfWar ill-
nesses, conditions associated with silicone
breast implants, and various fatigue syn-
dromes-may represent either mild chronic
cases ofporphyria, or, at least in part, man-
ifestations of acquired abnormalities in
heme synthesis. Although diagnoses ofpor-
phyria and porphyrialike conditions in
such cases are commonly dismissed by
other clinicians and researchers, these diag-
noses are increasingly put forth as objective
justification for recommending major
lifestyle modifications and therapeutic
interventions in individual cases.
This article reviews pertinent medical
and scientific literature in order to provide
a foundation to address current issues
related to environmental chemical expo-
sures and possible disturbances ofheme syn-
thesis. The first three sections ofthis review
provide necessary background information
about heme synthesis and the classification
and biochemistry of porphyria; more
detailed information is available in the
cited general references (1-10).
Heme Synthesis
Heme is a biological compound that, when
combined with certain proteins, plays a
central role in a variety ofvital physiologic
functions, including oxygen binding and
transport (hemoglobin and myoglobin), res-
piratory electron transport (cytochromes a,
a3, bl, c, and cl), activation and decomposi-
tion ofhydrogen peroxide (catalase and per-
oxidase), and other oxidation-reduction
functions (cytochromes P450 and b5). Heme
synthesis, which is often also referred to as
porphyrin metabolism, occurs in all human
cells. It is especially productive in the eryth-
ropoietic cells in bone marrow, where
nearly all ofthe heme is used for hemoglo-
bin, and in the liver, where the heme is
primarily needed in cytochrome P450.
Heme, or iron-protoporphyrin IX, is
produced by a metabolic pathway that
involves eight enzyme-controlled steps (see
below and Figure 1).
Succinyl CoA and glycine are com-
bined to form 6-aminolevulinic acid
Cytoplasm
4c+
Uroporphyrinogen
5i
Coproporphyrinogen I
6-Aminolevulinic acid
2
Porphobilinogen
3
Hydroxymethylbilane
+4
Uroporphyrinogen III
5b
Coproporphyrinogen IlIl
Figure 1. Heme Biosynthesis Pathway. Numbers designate individual enzyme-catalyzed steps of heme biosynthe-
sis. Enzyme name, step 1, ALA synthase; step 2, ALA dehydratase; step 3, PBG deaminase (uroporphyrinogen syn-
thase); step 4, uroporphyrinogen-ill cosynthase; step 5, uroporphyrinogen decarboxylase; step 6,
coproporphyrinogen oxidase; step 7, protoporphyrinogen oxidase; step 8, ferrochelatase. "ALA is synthesized
within mitochondria in step 1 and then traverses to cytoplasm, where step 2 occurs. Coproporphyrinogen IlIl is syn-
thesized in cytoplasm in step 5 and then traverses into mitochondria, where step 6 occurs. bintermediate precur-
sors not shown for step 5(7-, 6-, and 5-carboxyl porphyrinogens) or step 6 (3-carboxyl porphyrinogen). cAlternative
pathway at step 4(hydroxymethylbilane to uroporphyrinogen 1) is not enzymaticallycatalyzed.
(ALA), an amino acid committed
exclusively to heme synthesis.
* Two ALA molecules are condensed to
form porphobilinogen (PBG), a mono-
pyrrole.
* Four PBG molecules are polymerized
to form the linear tetrapyrrole hydroxy-
methylbilane.
* Hydroxymethylbilane is converted
enzymatically to the cyclic tetrapyrrole
uroporphyrinogen III (or nonenzymati-
cally to an isomer, uroporphyrinogen I,
which does not act as an intermediate
in heme synthesis).
* Sequential decarboxylations produce
a series of7-, 6-, and 5-carboxyl pro-
phyrinogens and then coproporphy-
rinogen III.
* Further sequential decarboxylations
produce 3-carboxyl porphyrinogen and
then protoporphyrinogen IX.
* Protoporphyrinogen IX undergoes oxi-
dation to protoporphyrin IX.
* Protoporphyrin IX is chelated with fer-
rous iron to produce heme.
Heme and protoporphyrin IX are the
only directly formed intermediates in the
heme synthesis pathway that are actual
porphyrins rather than porphyrinogens.
However, porphyrinogens are readily oxi-
dized to the respective porphyrin forms,
particularly when removed from the body.
Most laboratory assays measure and report
porphyrinogens in porphyrin form. For the
convenience ofa summary term, we use the
term heme precursors loosely to include
measured porphyrin forms ofporphyrino-
gens as well as the true intermediates of
heme synthesis.
Classification of Porphyrias
Most types of porphyria are known to
occur only as inherited conditions; how-
ever, one type of porphyria [porphyria
cutanea tarda (PCT)] is known to occur in
either an acquired or an inherited manner.
The inherited porphyrias are attributable
to an autosomal dominant or autosomal
recessive genetic defect affecting a single
enzyme in the heme synthesis pathway but
rarely are attributable to coexistent defects
separately affecting two different heme-
synthesis enzymes.
Porphyrias historically have been classi-
fied in various ways (see Table 1), includ-
ing: specific enzyme(s) principally involved;
nature ofunderlying inherited defect, ifany
(autosomal dominant, autosomal recessive,
acquired); principal origin(s) ofthe excess
heme precursors (hepatic, erythropoietic,
mixed); usual temporal pattern ofsympto-
matic manifestations (acute or chronic);
and principal nature of symptomatic
manifestations (neurologic, neurocuta-
neous, cutaneous). These classifications
overlap and are not mutuallyexclusive.
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Table 1. Classification of porphyrias and lead intoxication.
Enzyme Principal originof
Incidence deficiency excessheme precursors Symptom pattem Symptoms
pattem stepno.' Erythropoietic Hepatic Acute Chronic Neurologic Cutaneous
Porphyrias
AIP AD 3 + + I 'C L -'.. --4---~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~., -.~~E"
V-14 .... W.. ...i.S
PCT ADovrr 5 + + +
HEP AR .+ + .
VP AD7 ± .1 i± SMI !i 1 w i 1wl11|1111!!1SB101111~~~~~~~~~~~~~~~~~~~~Mu1H 1k 'i~i~~ ~ ,,', ~ IVI%&W.-' --'flu.- [4~f444Wl.k.W~ lfll IM*
Lead intoxication Acquired 2,68b + + + + +
Abbreviations: AD, autosomal dominant inheritance; AR, autosomal recessive inheritance; +, usually present; ±, variably present. aHeme synthesis enzyme designated by step
number (see Figure 1). blhere is apparent interference by lead with these steps. In cases of lead intoxication, there may be mechanisms other than lead inhibition of the
enzymes at steps 6 and 8 [Rossi (11)].
Porphyrias withNeurologic
Manifestations
Symptoms in the neurologic porphyrias
[ALA dehydratase (ALA-D) deficiency por-
phyria (ADP) and acute intermittent por-
phyria (AIP)] and noncutaneous symptoms
in the neurocutaneous porphyrias [heredi-
tary coproporphyria (HCP) and variegate
porphyria (VP)] tend to occur in intermit-
tent acute attacks, with variable degrees of
symptom presence between attacks. Clinical
onset of the neurologic and neurocuta-
neous porphyrias usually occurs in postpu-
bertal adolescents or adults; attacks are
more common in women than men. Only
six cases ofADP have been reported (7).
AIP is one of the more prevalent types of
clinically manifested porphyria, at least in
the United States.
All the neurologic and neurocutaneous
porphyrias (except ADP) are classified as
hepatic porphyrias because the liver is a
principal site in which the enzyme defi-
ciency manifests itselfbiochemically. Liver
function abnormalities are common but are
generally mild or moderate (12). Several
studies have indicated that individuals with
AIP are at risk for developing hepatocellular
carcinoma (13-15). The principal site of
enzyme expression has not been identified
clearly for the small number of patients
reported to have ADP.
The neurologic manifestations of acute
attacks are indistinguishable for the various
neurologic and neurocutaneous porphyrias,
and these conditions are differentiated by
biochemical or genetic testing. The princi-
pal manifestations reflect broad dysfunction
ofthe nervous system. Frequent symptoms
include: abdominal pain, constipation, nau-
sea, vomiting, tachycardia, hypertension,
fever (i.e., autonomic nervous system);
weakness, back and extremity pains,
localized or extensive pareses or paralysis,
paresthesias, hypoesthesias (i.e., peripheral
nervous system); and psychiatric or behav-
ioral symptoms (i.e., central nervous
system). Hyponatremia may reflect inap-
propriate secretion ofantidiuretic hormone
(i.e., hypothalamus). The intensity of
symptoms, particularly pain, can be severe;
associated physical signs, however, are
commonly either absent or disproportion-
ately less intense. Symptoms are generally
less severe in HCP (7).
Most individuals who possess the
genetic defect associated with one of the
neurologic or neurocutaneous porphyrias
show no recognizable clinical manifesta-
tions ofporphyria throughout their lives.
Only about 10% ofindividuals genetically
predisposed to AIP or VP, and probably no
more than one-third of those predisposed
to HCP, ever develop the characteristic
attacks of acute symptoms (4,7,16-18). If
and when symptoms develop in a geneti-
cally predisposed individual, the initial
onset and any subsequent recurrences often
are linked to precipitating factors such as
use of a therapeutic drug, exposure to a
provocative chemical, alcohol consump-
tion, tobacco smoking, an infection, the
menstrual cycle, or fasting (1).
The frequency and severity ofsymptom
attacks vary widely both among and within
individuals. In most cases, symptom
attacks have discernible onsets, are charac-
terized by moderate or severe pain, last sev-
eral days or longer (up to weeks or months),
and are followed or separated by periods
of clinical remission. Attacks are usually
recurrent but not necessarily (18). Some
manifestations of acute attacks can persist
after the other clinical and biochemical
manifestations subside or resolve; this is
particularly true for peripheral motor neu-
ropathy, which can take up to 1 year to
resolve or can become permanent (19,20).
Permanent neurological deficits are not
necessarily accompanied by heme precursor
abnormalities when a patient's porphyria is
otherwise in remission.
In contrast to the typical acute presen-
tation, symptoms in some cases can occur
nondistinctly in time and/or be relatively
mild and some symptoms, particularly pain
or psychiatric manifestations, can become
chronic, often with variable severity over
time (7,9,21). Given such complex presen-
tations as well as the frequent paucity of
physical signs, the diagnosis ofporphyria
can be delayed or missed entirely. Accord-
ingly, screening surveys of psychiatric
inpatients have reported a relatively high
prevalence of individuals with previously
unrecognized porphyria (22-24). One
recent study, however, found no significant
increase in major psychiatric illness among
344 consecutive patients with AIP (25).
Porphyrias withNeurologicand/or
Cutaneous Manifestations
The neurocutaneous porphyrias, VP and
HCP, can manifest cutaneous lesions as
well as acute noncutaneous symptom
attacks. One review of 110 cases of HCP
reported that 30% experienced acute pho-
tosensitive responses, usually in association
with acute symptom attacks (16). In con-
trast, acute photosensitivity is not common
in VP; the cutaneous lesions tend to be
chronic and they occur more often in indi-
viduals who do not have acute symptom
attacks than in those who do (26,27). The
cutaneous lesions of VP are particularly
common in hot climates-about 75% in a
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series ofSouth African patients with clini-
cally active VP (27). The cutaneous lesions
of VP and chronic cutaneous lesions of
HCP cannot be distinguished clinically or
histologically from PCT (see below).
Porphyriaswith Cutaneous
oanifestations
The cutaneous porphyrias include all the
porphyrias classified as erythropoietic [con-
genital erythropoietic porphyria (CEP),
hepatoerythropoietic porphyria (HEP), and
erythropoietic protoporphyria (EPP)] plus
the nonerythropoietic porphyria PCT. The
hereditary and acquired forms ofPCT usu-
ally manifest first in adulthood, whereas
clinical onset ofthe erythropoietic porphyr-
ias usually occurs in infancy or childhood.
There is no gender predilection in PCT,
although in the past it has tended to occur
more often in men. The erythropoietic por-
phyrias are relatively uncommon: fewer
than 200 cases ofCEP and fewer than 20
cases ofHEP have been reported (7,28,29).
The cutaneous manifestations ofCEP,
PCT, and HEP (and VP and HCP) can be
difficult to distinguish on the basis ofclini-
cal or histologic appearance, although the
lesions of the autosomal recessive condi-
tions, CEP and HEP, are usually more
severe. Cutaneous manifestations include:
skin fragility, vesiculobullous skin erup-
tions evolving into crusted ulcers, and
residual hyperpigmentation or scarring,
primarily occurring in sun-exposed areas of
the body (7,30). Facial hypertrichosis is
also common. The pattern ofEPP differs
substantially and is generally less severe
than in the other cutaneous porphyrias; it
is characterized by acute photosensitivity
manifesting as pain, pruritus, and erythema
with exposure as short as minutes, and gen-
erally without vesiculobullous lesions or
scarring unless sun exposure is prolonged
(30,31). Liver injury is usually not found
with the cutaneous porphyrias other than
in some patients with EPP, in which case it
can be severe and potentially fatal.
PorphyriaCutneaTarda
Porphyria cutanea tarda is one ofthe most
prevalent types of porphyria; it occurs
more often as a sporadic condition than as
a familial inherited condition. The genetic
defect associated with the familial form is
inherited in autosomal-dominant manner.
Hepatic uroporphyrinogen decarboxylase
(Uro-D) activity is decreased in all forms of
PCT; erythrocyte Uro-D activity, however,
is normal in the sporadic form but is
decreased in all but a small subgroup of
familial cases (32). The sporadic and famil-
ial forms ofPCT usually occur in associa-
tion with exogenous factors such as alcohol,
oral estrogens, iron, and certain chemicals,
orwith certain medical conditions, particu-
larly liver diseases; both are successfully
treated in the same manner (2,7). Familial
PCT, therefore, can be regarded at least
partially as an acquired condition in which
the inherited enzyme deficiency may only
increase an individual's susceptibility to
disease (33).
PCT is usually associated with some
degree ofliver abnormality (2,3,8). Liver
function tests are nearlyalways abnormal to
some degree. Moderate siderosis and vari-
ous degrees offibrosis or necrosis are often
found upon biopsy, and cirrhosis develops
in a small proportion ofpatients. It is com-
mon for PCT to develop in individuals
with preexisting liver disease ofa variety of
types, particularly alcoholic liver disease or
chronic hepatitis C (34-38). Patients with
chronic liver disease also can develop mild
or moderate degrees of porphyrinuria
(increased urine porphyrins) in biochemical
patterns that can be consistent with PCT
but without associated cutaneous lesions
(see "Chronic Hepatic Porphyria") (2,39).
Patients with PCT are reported to be at risk
for developing hepatocellular carcinoma
(13,40-42); conversely, some benign or
malignant liver tumors can overproduce
uroporphyrin and induce PCT (43-45).
Biochemistry of Porphyrias
Deficient activity of a heme-synthesis
enzyme results in accumulation of the
heme precursors proximal to the defi-
ciency, although overall production of
heme is generally adequate (1-10,46). The
water solubility of the heme precursors
decreases progressively with successive steps
ofheme synthesis. Excess protoporphyrin
is excreted exclusively in stool; copropor-
phyrinogen, uroporphyrinogen, and the 7-,
6-, and 5-carboxyl porphyrinogens are
excreted in both urine and stool, and ALA
and PBG are excreted predominantly in
urine. Porphyrins in stool undergo varying
degrees of transformation by normal
enteric bacteria (47,48). When a heme-
synthesis enzyme deficiency is expressed
more in one tissue than another, heme pre-
cursors that accumulate in one tissue can
be transported in blood to other tissues,
with subsequent conversion to later inter-
mediates in the heme synthesis pathway;
experimental ALA loading, for example,
leads to prompt coproporphyrinuria in
humans (49-51).
In general, the neurologic (and neuro-
cutaneous) porphyrias are characterized by
excessive excretion ofthe porphyrinogen
precursors, ALA and PBG, in urine; the
cutaneous (and neurocutaneous) porphyr-
ias are characterized by the accumulation
ofporphyrins in blood and excessive excre-
tion ofporphyrins in urine and/or stool
(46,52-54). Individual types ofporphyria
can be differentiated by the pattern of
heme precursors (i.e., the absolute values
and the ratios to each other) in a patient's
urine, blood, and stool, ifcollected either
during or soon after attacks ofneurologic
symptoms or while porphyric skin lesions
are actively manifested. Excretion ofALA
and PBG in urine usually normalizes
within several weeks following an acute
attack in VP or HCP (16,26,27); in AIP,
urine excretion commonly subsides but
might not completely normalize during
remissions (19,20). Compared to an acute
attack, urine porphyrinogen precursors
(i.e., ALA and PBG) may be lower in VP
when solely cutaneous lesions are present,
but urine porphyrins are still increased to
diagnostic levels (27). Porphyrins are
always increased in the plasma ofpatients
with active cutaneous lesions (10).
When an individual has symptomatic
manifestations ofa porphyria (i.e., when
dinically active and not latent or in remis-
sion), the level of the most excessively
excreted heme precursor is typically at least
several-fold greater than the values reported
for the upper limit of normal. In reports
describing the neurologic porphyrias, for
example, urine ALA and PBG in AIP
increased acutely to 8 to 150 and 30 to 200
mg/day, respectively (normal upperlimits, 3
to 7.5 mg/day, depending on the labora-
tory) (7,20,26,55-57); and in ADP, urine
ALA was markedly elevated and urine and
erythrocyte porphyrins were elevated up to
100 times (7,10). In reports ofthe neurocu-
taneous porphyrias, urine coproporphyrin
in HCP increased acutely to 4 to 190 times
normal (16,58). In VP, one small case series
reported the lowest values ofurine ALA,
PBG, uroporphyrin, and coproporphyrin in
acute attacks to be 9, 12, 190, and 27 times
the mean control values, respectively (26),
which was consistent with the higher aver-
agevalues reported in alarger series (27). In
reports ofthe cutaneous porphyrias, urine
uroporphyrin in PCT increased to about
10 to 375 times normal in over 300 reported
cases (except in one case (59), where a
single value was within normal range)
(60-70), and in EPP, reported erythrocyte
protoporphyrin values ranged from 2.4 to
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90 times normal (31,65,71), with the
exception of a single patient in whom it
was elevated by only a factor of 1.4 (31).
Finally, in reports of the less common
(autosomal-recessive) cutaneous porphy-
rias, urine porphyrins in CEP were 20 to
60 times normal (7) and in HEP, urine
uroporphyrin increased by at least 20-fold
and erythrocyte porphyrins increased by
5- to 10-fold (28,29,72). Plasma porphy-
rin concentrations are markedly increased
when there are active skin lesions due to
any cutaneous porphyria (10).
Secondary Porphyrinuria
Some of the tests used to diagnose the
porphyrias are nonspecific and are abnor-
mal in a variety ofcircumstances other than
the porphyrias. Porphyrinuria can be
caused by porphyrias, by a number ofother
medical conditions, especially those affect-
ing the liver or bone marrow, and by a vari-
etyofexogenous factors such as alcohol and
certain drugs and chemicals that disturb
heme synthesis or stress heme-dependent
metabolism (1,73-76). The term sec-
ond4ry porphyrinuria is commonly applied
to the porphyrinuria occurring with condi-
tions and factors lacking a primary enzyme
defect in heme synthesis. It usually involves
mild or moderate coproporphyrinuria, with
no or little excess uroporphyrin in urine,
and is also often called coproporphyrinuria
or secondary coproporphyrinuria.
The detection of porphyrinuria has
potential utility as a biological indicator of
exposure to chemicals with porphyrinogenic
properties and as a staging measure for sub-
clinical development and progression of
chronic hepatic porphyria (see "Chronic
Hepatic Porphyria and Environmental
Chemicals and Effects on Measures of
Heme Synthesis"). However, with the
noteworthy exception of lead poisoning
(see "Environmental Chemicals and Effects
on Measures ofHeme Synthesis"), the por-
phyrin excess in secondary porphyrinuria
has no recognized clinically detectable
consequences of its own. Most reviewers
attribute symptoms associated with sec-
ondary porphyrinuria (other than lead poi-
soning) to the condition or agent causing
the porphyrinuria or to an unrelated cause,
not to a disturbance in heme synthesis
(2,3,10,75,77-81). Still, although the
porphyrinuria itself may be benign, an
associated medical condition may be far
from benign.
Accumulation or excessive excretion of
heme precursors does not necessarily mean
there is a deficiency of a heme pathway
enzyme(s); other possible mechanisms
exist. Increased erythropoiesis can produce
increases in urine coproporphyrin, as
demonstrated by induced anemia in experi-
mental animals (82). Coproporphyrin nor-
mally is excreted in bile and in urine, and
impaired biliary excretion in hepatobiliary
disease leads to increased coproporphyrin
excretion in urine (83). Stimulation of
hepatic heme synthesis (e.g., by certain
drugs) in the absence ofdeficiency ofany
heme-synthesis enzymes can lead to
increased coproporphyrin excretion. The
kidney (primarily the epithelium of the
proximal tubules) has been identified as a
major source of porphyrins (primarily
coproporphyrin) in the urine of normal
and porphyric individuals as well as lead-
and mercury-poisoned individuals (84-87).
It is conceivable that toxic effects on renal
tubular function could lead to increased
urinary loss ofporphyrins along with other
substances handled by renal tubules without
inhibition ofheme synthesis.
Chronic Hepatic Porphyria
Based on clinical experience (77,88), and
with supporting evidence from animal
experiments (89), Doss (39,75,90) has
described the potential for chronic nonspe-
cific disturbances in hepatic heme synthesis
to make a transition from secondary copro-
porphyrinuria and progress through several
clinically latent stages ofchronic hepatic
porphyria [(CHP) Types A, B, and C] to
PCT (CHP Type D). Each stage in the
Doss model (75,88) is differentiable by
urine porphyrin quantities and patterns
(i.e., initial accumulation ofuroporphyrin
and later heptacarboxyl porphyrin in the
liver), progressively greater degrees ofsub-
clinical liver injury, and ultimately the
occurrence ofcutaneous lesions. The tran-
sition from secondary coproporphyrinuria
to CHP requires either a genetic defect or
toxic inhibition of Uro-D activity in the
liver, generally in combination with liver
disease and precipitating factors such as
alcohol or estrogens.
The Doss model, however, is not uni-
formly accepted as valid. The evidence in
humans for the Doss model comes from
cross-sectional studies ofpatientpopulations,
not longitudinal studies (77,88). There are
no well-documented cases of individual
patients actually progressing through CHP
Types A, B, and C to PCT, and it has not
been demonstrated that mild degrees of
porphyrinuria, particularly coproporphy-
rinuria, predict the potential for an indi-
vidual to develop PCT. The early stages in
the CHP model are characterized primarily
by coproporphyrinuria, which can occur
nonspecifically with liver disease and may
reflect a separate phenomenon. There is no
evidence or reason to predict that hepatic
Uro-D deficiency is manifested initially by
coproporphyrinuria before uroporphyrin-
uria. In addition, there is evidence that
the kidney may be the primary source of
coproporphyrin and other porphyrins
excreted in normal urine and may also be a
major source in certain porphyrias and
toxin-induced porphyrinurias (84,91,92).
Environmental Chemicals
and Effects on Measures
of Heme Synthesis
In individuals who are genetically predis-
posed to developing an acute or cutaneous
porphyria (e.g., inheriting one allele), the
biochemical and clinical manifestations of
porphyria can be triggered by a variety of
exogenous factors including certain chemi-
cals and therapeutic drugs, alcohol con-
sumption, tobacco smoking, infections,
and dietary factors, as well as by certain
medical conditions and endogenous factors
such as the menstrual cycle (1). Exposure
to the sun can trigger cutaneous manifesta-
tions of porphyria if an excess of por-
phyrins already exists. Therapeutic drugs
are particularly well recognized as possible
precipitants ofacute porphyria and current
lists ofdrugs classified as unsafe and drugs
thought to be safe for use in acute porphyr-
ias are maintained (93-95). Exogenous fac-
tors can also cause changes in the heme
synthesis pathway, even in the absence of
genetic predisposition; in some cases, these
acquired changes have been reported to
cause PCT.
A number of chemicals, including
halogenated hydrocarbons and metals, are
known to be porphyrinogenic (i.e., capable
of inducing changes in heme synthesis,
with subsequent overproduction and
excessive excretion ofheme precursors) in
experimental animals, generally with expo-
sure by ingestion and with doses much
greater than the range ofhuman experience
(96-98). In addition to possible inter-
species differences, the differences in dose
and pattern ofexposure limit the ability to
extrapolate from experimental animal
studies in order to assess the potential risks
ofspecific chemicals for humans. Unfortu-
nately, there has been only limited system-
atic study of the subject in humans. In
humans, with the noteworthy exceptions of
porphyria caused by hexachlorobenzene
(HCB) ingestion and the porphyrinuria
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caused by lead, reports of porphyria or
porphyrinuria attributable to chemical
exposures have been infrequent. The
reported findings have generally been
linked to chronic industrial exposures,
industrial accidents, or environmental
exposures that were much higher than
usually encountered.
Hechlorobenzene
The most noteworthy incident ofchemical-
induced porphyria in humans occurred
in Turkey during the late 1950s, when
approximately 3000 cases of PCT devel-
oped from the ingestion of seed wheat
treated with fungicides containing about
10% HCB (99-106). The wheat was
treated in anticipation of use for planting
but was instead used for human consump-
tion. The syndrome commonly consisted
ofweight loss, muscle wasting, weakness,
hepatomegaly, thyromegaly, arthritic
changes, gross porphyrinuria, hypertri-
chosis, and photosensitive dermopathy
(99,102). The dermopathy was usually
hyperpigmented and had vesiculobullous
lesions that eventually ulcerated, were com-
monly complicated by infections, and left
depigmented scars and often disfiguring
contractures. Active skin lesions tended to
abate within a month after HCB exposure
ended but often recurred subsequently in
summer months, even in the absence of
any new exposure to HCB. Children were
affected disproportionately more than
adults. Some reports noted the absence of
abdominal crises, mental disturbances, and
other neurologic complications (99,100);
others noted the presence ofabdominal colic
and muscle weakness during the acute phase
(102). Follow-up studies up to 30 years
later reported that a majority ofthe patients
studied had cutaneous residua, arthritic
deformities, thyromegaly (particularly in
women), and neurologic manifestations
includingweakness, paresthesias, andsensory
shading; smaller proportions of patients
had myotonia or cogwheel rigidity without
other extrapyramidal signs (103-106).
Administration of HCB to experimen-
tal animals causes a deficiency ofhepatic
Uro-D and a pattern ofporphyrin accumu-
lation closely resembling that in human
PCT (89,107-111).
Dioxin
Laboratory experiments have demonstrated
that tetrachlorodibenzodioxins (dioxin(s)
or TCDDs) in high ingested doses are por-
phyrinogenic in rodents (112,113), but the
evidence in humans is mixed. The strongest
human evidence is from two workplace
studies. In 1964, a study at a New Jersey
chemical plant that produced the herbi-
cides 2,4-dichlorophenoxyacetic acid
(2,4-D) and 2,4,5-trichlorophenoxyacetic
acid (2,4,5-T) described two workers with
PCT and another with possible PCT, and
also reported that urine uroporphyrins
were positive in 8 of 26 other workers
(114). Most workers studied had chlo-
racne, prototypically caused by dioxin,
which was then a frequent contaminant
of 2,4,5-T production. Another study of
55 workers arriving at a hospital from a
Czechoslovakian herbicide manufacturing
plant found a high prevalence ofchloracne,
11 workers with PCT, and slightly
increased urine uroporphyrin (< 100 pg/
24 hr; reference range not stated) in 21%
of those tested (115). One worker in a
TCDD-contaminated workplace developed
PCT, sarcoma, and probable chloracne; the
combined occurrence ofthese rare condi-
tions suggested an etiological relation to
the TCDD exposure (116,117). Other
workplace studies, however, have been less
demonstrative. A later study at the same
New Jersey plant found no active cases of
PCT and no workers with abnormal urine
excretion of heme precursors except one
worker who formerly had severe PCT
(118). Maintenance workers, who had the
highest chemical exposures, were found to
have higher average urine coproporphyrin
levels than otherworkers, but their individ-
ual levels were all within normal limits.
Two separate later studies ofherbicide pro-
duction plants (one ofwhich included the
New Jersey plant mentioned above) (119)
were both negative (120).
Limited evidence is also available from
community studies. An explosion at a
chemical plant in Seveso, Italy, in 1976
contaminated the surrounding environ-
ment with TCDDs. Two related individ-
uals who were found to have a preexisting
familial defect in Uro-D were reported to
manifest PCT after the explosion without
another evident precipitating factor (121).
Among 60 Seveso residents from other
families, 8 were reported to have secondary
coproporphyrinuria and 5 had a transition
constellation to CHP Type A (121) (see
"Chronic Hepatic Porphyria"). Another
study, of 115 Seveso residents, found that
84% had urine porphyrin patterns consis-
tent with coproporphyrinuria or CHP
Type A, with the greatest prevalence and
degree ofabnormality in residents from
areas ofhighest contamination (122). A
later study, however, reported chloracne
but no PCT attributable to TCDDs
among Seveso children and adolescents
(123,124). In two studies of Missouri
communities where TCDD-contaminated
waste oil had been sprayed for dust control
over several years, there were no cases of
PCT, but one study found significantly
higher mean uroporphyrin levels in urine
and higher prevalence of elevated urine
uroporphyrin values (> 13 pg/g creatinine
(cre) in 16%, vs 7% controls) among
154 residents of a contaminated mobile
home park compared to matched control
subjects (125,126).
OtherHalogenatedHydrocarbons
A number of halogenated hydrocarbons
have been demonstrated experimentally to
be porphyrinogenic in exposed animals or
in in vitro tests; these are well summarized
in Strik et al. (96) and Marks (97) and
will not be described in this review. The
reported human experience is less exten-
sive. Haberman et al. (127) mentioned
that a case of PCT manifested itselfsoon
after agricultural application of DDT.
Lynch et al. (128) reported a case of PCT
in association with hepatitis, which was
attributed to chronic toxic exposure and
presumed to be a polychlorinated phenol
unintentionially synthesized on a regular
basis by mixing cleaning agents containing
benzylchlorophenol and sodium hypochlo-
rite. A worker with severe acute methyl
chloride intoxication had marked increase
in urine and fecal excretion of copropor-
phyrin but not uroporphyrin or protopor-
phyrin; the coproporphyrinuria decreased
in association with clinical improvement
(129). Evaluation of46 workers exposed to
vinyl chloride in a polyvinyl chloride pro-
duction process found that 36 had copro-
porphyrinuria (<820 nmol/24 hr; normal
(nl) < 130), including 4 who also had
mildly increased excretion ofuroporphyrin
and heptacarboxyl porphyrin in urine (130).
A study ofMichigan farm families exposed
to polybrominated biphenyls (PBBs) by
ingestion ofcontaminated meat and dairy
products found that 11 of 126 persons had
coproporphyrinuria (93-218 pg/liter;
nl<78), including 4 with mild uroporphy-
rinuria (29-59 pg/liter; nl<24) (131). Of
20 individuals in Taiwan, 2 years after poi-
soning with polychlorinated biphenyls
(PCBs) in food oil, 3 had elevated uropor-
phyrin in urine (50-139 pg/liter; controls,
7-22), 1 ofwhom, plus 5 others, had ele-
vated coproporphyrin (61-255 pg/liter;
controls, 2-48) (132). Two separate
studies of87 similarly poisoned individuals
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in Yusho, Japan, about 10 years after the
event, found no differences in urine por-
phyrins compared to those ofcontrols and
identified PCT in 1 person whose history
was complicated by alcohol use (133,134).
Total urine porphyrins were not signifi-
cantly different from those ofcontrols in
168 chemical plant workers exposed to
either allylchloride, hexachlorocyclopenta-
diene, epichlorohydrin, or endrin (135).
Lead
Lead absorption, both acute and chronic, is
well documented to affect heme synthesis
(11). Lead causes accumulation of zinc
protoporphyrin (ZPP) in erythrocytes and
large increases ofALA and coproporphyrin
in urine. Lead reversibly inhibits ALA-D
and also appears to interfere with the func-
tion ofcoproporphyrinogen oxidase and
ferrochelatase, possibly by mechanisms
other than direct enzyme inhibition
(11,98,136,137). It is conceivable that the
coproporphyrinuria occurs by the same
mechanism as in ALA loading of normal
subjects (Biochemistry ofPorphyrias).
There is evidence that ALA-D poly-
morphism may influence lead toxicokinet-
ics. The ALA-D enzyme is comprised of
eight identical subunits coded by an auto-
somal gene, at which there are two com-
mon alleles (138). The ALA-DI allele has
about 80 to 90% prevalence in studied
European and American population sam-
ples; the ALA-D2 allele, about 10 to 20%
(138-142). The three associated pheno-
types (1-1, 1-2, 2-2) have similar enzyme
activities in erythrocytes. A number of
studies have reported that individuals with
the ALA-D2 allele, particularly the
homozygous ALA-D 2-2 phenotype, have
higher blood lead levels on average than
individuals with the ALA-D 1-1 phenotype
and comparable lead exposures (142-145).
The possible mechanism of this reported
phenomenon is not known, although it has
been speculated that ALA-D subunits
coded by the ALA-D2 allele might bind
lead more efficiently (146). The possible
clinical relevance also is unclear. Some
investigators have suggested that ALA-D2
might render individuals more susceptible
to lead poisoning (143,145); others have
suggested that ALA-D2 might protect
against lead effects (147).
Lead intoxication is generally classified
as a secondary porphyrinuria rather than
an acquired porphyria, although some inves-
tigators have classified it as a porphyria,
noting clinical and biochemical similarities
with the acute porphyrias (see Table 1),
particularly ADP (39,148-150). It is not
known to what degree the manifestations
oflead poisoning might be attributable, if
at all, to the associated disturbance in heme
synthesis apart from the directly neurotoxic
properties oflead, but there is evidence the
disturbed heme-forming system may have
some contributing role (151,152).
The reported interaction between lead
exposure and genetic deficiency ofALA-D
is noteworthy. ADP is attributable to
homozygous autosomal-recessive defects
affecting ALA-D, with near total loss of
enzyme activity; heterozygous carriers of
the defect have only partial loss ofALA-D
activity and usually have no associated
symptoms (153). However, the heterozy-
gous defect appears to increase the vulnera-
bility of the individual to the effects of
exogenous agents such as lead, which
reduce ALA-D activity. In case reports of
individuals who had a heterozygous defect
affecting ALA-D and were exposed to
lead, the biochemical abnormalities and
clinical features of illness were consistent
with lead intoxication but were much
more severe than expected for their mildly
elevated blood lead levels (22-43 pg/dl)
(149,154,155). The prevalence ofthe het-
erozygous defect in the general population
has been estimated variably to be below
1% (149) or as high as 2% (156).
OtherMetals
Mercury, arsenic, and other metal exposures
are also reported to affect heme synthesis in
humans, although the associated levels of
porphyrinuria are lower than those seen
with lead. In a survey ofdentists attending
an annual professional meeting, those who
were found to have >20 pg/liter mercury in
spot urine samples also had 2- to 3-fold
higher levels of coproporphyrin in urine
(42 ± 18 pg/g cre or 74 ± 8 pg/liter;
mean ± SD) than those with no urinary
mercury (coproporphyrin 28 ± 12 pg/g cre
and 23 ±6 pg/liter) (87). Urine uropor-
phyrin excretions did not differ signifi-
cantly; however, pentacarboxyl porphyrin
and an atypical porphyrin tentatively iden-
tified as keto-isocoproporphyrin were sig-
nificantly elevated in urine. A study of
random urine samples from 52 workers
exposed to inorganic and organic mercury
(median urine mercury about 500 pg/liter)
found that 23% had elevated copropor-
phyrin levels (>70 pg/liter and up to 159
pg/liter) compared to only 3% ofcontrol
subjects (157). Similarly, astudy ofarsenic-
exposed smelter workers (urine arsenic
129 ± 109 pg/g cre in the high-exposure
group) found more than twice as much
coproporphyrin (63±30, range 18-171,
pg/g cre) but comparable amounts of
uroporphyrin in morning urine specimens,
relative to those of nonexposed control
subjects (coproporphyrin 27± 14, range
2-57, pg/g cre) (158). In another study,
individuals exposed to arsenic in drinking
water (urine arsenic mean 65, range 1-130
pg/liter) were reported to have no signifi-
cant increase in urine porphyrin levels rela-
tive to those ofa control group, although
most exposed individuals did have inver-
sion ofthe urine coproporphyrin/uropor-
phyrin ratio (76%, vs 32% of controls)
(159). Downey (160) reported a case of
acute intermittent porphyria (laboratory
results not presented), with symptoms
including transient dermatitis, severe
abdominal pain, diarrhea and vomiting,
dyscoordination, memory loss, and visual
hallucinations, all ofwhich developed soon
after placement ofdental prostheses (con-
taining 76% palladium and 10% copper)
and resolved "almost immediately" after
removal ofthe prostheses.
Experimental animal and in vitro
studies have demonstrated a number of
other metals to be porphyrinogenic, includ-
ing aluminum, cadmium (with arsenic or
lead), cobalt, gallium arsenide and others;
again, these data are summarized in detail
in other reviews [Marks (97), Woods (98),
Fowler et al. (161)].
OtherChemicals
Bleakley et al. (162) noted, in describing
elevated fecal porphyrins in rats with sub-
chronic cutaneous exposure to diazinon, "in
a number ofcases seen [ofPCT in humans]
... a history of contact with pesticides, in
particular with diazinon." A study of 17
pulp production workers exposed to hydro-
gen sulfide and methylmercaptan reported
reduced activities ofALA synthase, ALA-D,
and ferrochelatase (relative to reference
ranges) in the reticulocytes of 8, 1, and 5
workers, respectively, aswell as lowerythro-
cyte protoporphyrin levels in 7 workers
compared to control values (163). In two
reported case series ofacuteporphyria, paints
and solvents were described as triggers of
acute symptoms in a number ofgenetically
predisposed individuals (26,164).
Measures ofHemeSynthesis
asBiologicalMarkers
ofChemicalExposure
Measurements of the status of heme
synthesis, particularly measurements of
excreted heme precursors, have potential
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field and clinical utility as biological
indicators ofchemical exposure and chemi-
cal effect on body functions (98,165). This
is well illustrated by the extensive experi-
ence with lead, where measurements of
protoporphyrin in blood [e.g., free erythro-
cyte protoporphyrin (FEP) and ZPP] and
ALA and coproporphyrin in urine have
been used, and in the case ofZPP are still
used, as sensitive markers oflead intoxica-
tion. Animal experiments have demon-
strated that a number of metals produce
characteristic patterns ofchange in the uri-
nary excretion ofheme precursors, that the
induced disturbances in heme synthesis are
typically associated with ultrastructural
changes and alterations ofother subcellular
processes, and that these measurable changes
occur before the effects of metal exposure
would be clinically evident (98,161).
Therefore, measurements ofheme precur-
sors may offer a means ofdetecting harm-
ful effects ofspecific chemical exposures
in humans at stages ofbiological response
to exposure that are still preclinical and
are presumably most reversible. As the pre-
ceding sections indicate, however, only a
small number ofstudies in humans have
attempted to assess the utility and validity
ofheme precursor measurements or other
measures ofthe status ofheme synthesis as
markers ofexposure or preclinical disease in
chemicallyexposed humans.
Unexplained Chemical-
associated Illnesses
and Measures of
Heme Synthesis
It has recently been proposed that a variety
of chemical-associated illnesses for which
there are no widely accepted specific diag-
nostic tests or etiologic explanations-such
as MCS syndrome, Persian GulfWar ill-
nesses, conditions associated with silicone
breast implants, and various fatigue syn-
dromes-may represent either mild chronic
cases ofporphyria, or at least in part, mani-
festations of acquired abnormalities in
heme synthesis (166-177).
The MCS syndrome (178-180) has
been defined by Cullen (181) as "an
acquired disorder characterized by recur-
rent symptoms, referable to multiple organ
systems, occurring in response to demon-
strable exposure to many chemically unre-
lated compounds at doses far below those
established in the general population to
cause harmful effects." No physiologic test
has been widely accepted as correlating
with symptoms in MCS syndrome,
although a variety of immunologic and
neurologic tests have been described as
abnormal or diagnostic based on clinical
series data. Ofnote, however, one blinded
prospective controlled study evaluated a
panel of immunologic tests offered by a
laboratory with recognized interest in the
evaluation of individuals with chemical
sensitivities, and found that the tests did
not distinguish between MCS patients and
control patients (182). Still, in spite of
continued debates about the origins of
MCS syndrome, there is little doubt that it
can be associated with substantial sympto-
matic distress, major lifestyle disruption,
and severe degrees ofinability to perform
usual activities ofwork and daily life.
To date, the hypotheses ofporphyric
mechanisms in these otherwise unex-
plained syndromes are based only on indi-
vidual cases or case series characterized by
relatively mild increases in porphyrin
excretion and/or decreases in activity of
various heme-synthesis enzymes. The data
reported to date have not identified any
characteristic unifying pattern(s) among
the laboratory test results. Donnay and
Ziem (171) reported in 1995 that two
medical practices in Washington State had
found excess porphyrins and/or enzyme
abnormalities in patterns that did not
match those ofany inherited porphyrias in
over 70% ofmore than 150 MCS patients
with symptoms of porphyrinopathy.
Morton (172) described laboratory find-
ings for 38 individuals with chemical sensi-
tivities and deficient activity ofat least 1 of
5 tested heme-synthesis enzymes. Although
he did not distinguish between the mar-
ginal and low laboratory reference ranges
in defining deficiency (see "Limitations of
Laboratory Measures ofHeme Synthesis"),
22 (58%) had deficiency ofcoproporphy-
rinogen oxidase (Copro-O), 13 (34%) had
deficiency ofprotoporphyrinogen oxidase,
and 27 (71%) had at least 1 excess por-
phyrin in feces or urine (values reported
only as yes or no). Of note, 7 of the 22
individuals with Copro-O deficiency and 4
of the 16 individuals with deficiency of
enzymes other than Copro-O had no
detected excess ofporphyrins in feces or
urine. Ziem and McTamney presented
supporting clinical data at a recent scien-
tific meeting; those data are not yet avail-
able for circulation (177).
Downey (168) described hereditary
coproporphyria in 13 patients (plus 7 family
members) who arrived at an oral stomatol-
ogy clinic with unexplained oral conditions
and multiple systemic complaints: 16 of 19
tested had abnormal Copro-O activity, 3
ofthose 16 had one other abnormal heme-
synthesis enzyme, and 14 of 14 tested had
elevated heme precursors in urine or stool.
Ofthe 16 abnormal Copro-O activity val-
ues, 14 were in the marginal reference
range (0.06-0.09 relative units) and the
other 3 values were just below the marginal
range (0.05 relative units) (182). Ofthe 21
elevated heme precursor values (most often
coproporphyrin), 17 (81%) were 1.1 to 1.8
times higher than the respective value
reported for the upper limit ofnormal, and
4 (2 in stool and 2 in urine) were 2.0 to
2.3 times higher (182). Downey (167)
mentioned that about 90% of62 patients
(including the above-described 19) were
found to have one or more heme-synthesis
enzyme abnormalities.
Two types ofhypotheses have been put
forth in explanation of such laboratory
findings occurring with otherwise unex-
plained chemical-associated illnesses. The
first hypothesis is that these illnesses are
actually porphyrias, in which illness is pre-
cipitated by environmental chemical expo-
sures in genetically predisposed individuals
(160,167,172). Proponents suggest that the
latent genetic traits for various porphyrias
are much more common in the general
population but were not recognized until
the recent increased availability oflabora-
tory assays for the activity ofheme-synthesis
enzymes. It is hypothesized that such genet-
ically predisposed individuals can manifest
porphyria symptoms in low-grade smolder-
ing or chronic and slowly progressive pat-
terns (without classically recognizable acute
attacks ofsevere symptoms) in response to
exposures to a variety ofsubstances such as
"formaldehyde, other aldehydes, heavy
vehicle exhaust fumes, perfumes, other fra-
grances, chlorine, chlorinated cleaning
agents, possibly any chlorinated hydrocar-
bon, substances in poorly ventilated build-
ings, and anything that triggers porphyria
symptoms" (172). It is contended that these
chronic symptom patterns are not necessar-
ily accompanied by diagnostic abnormali-
ties ofheme precursors, possibly because a
"limited attack especially on a small num-
ber ofcells or on cellswhere the heme path-
way is not a major functioning system or
where the affected cells do not have ready
access to external excretory processes may
not raise porphyrin precursors above nor-
mal levels" (167); measurement ofheme-
synthesis enzyme activities, therefore, is
regarded as critical to diagnosis.
The second hypothesis is that genetic
predisposition may not be an essential
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component of a porphyric mechanism
in MCS syndrome, and that reported
reductions in activity of heme-synthesis
enzymes might represent an acquired defi-
ciency attributable to exogenous toxic
agents or stressors, manifesting as either
an intoxication porphyria or some other
as-yet undefined disorder of porphyrin
metabolism (169,171). It is hypothesized
that "the heme pathway may be just one
of many sites in the body adversely
affected by exposure to toxic chemicals,
and that this interaction could account for
many of the cutaneous, neurological and
psychological symptoms reported by MCS
patients, including the most controversial
symptom of chemical sensitivity itself"
[A Donnay, personal communication;
(166)]. Some cases ofMCS syndrome are
predicted to be porphyric and the others
nonporphyric (171).
Limitations of
Laboratory Measures
of Heme Synthesis
In evaluating the symptomatic patient
with a suspected disturbance of the heme
synthesis pathway, the interpretation of
laboratory tests must consider the condi-
tions of sampling and the limitations of
those tests.
Methodologic Limitatons
Laboratory test results, in general, can be
compromised by a variety of factors,
including specimen integrity (reflecting
conditions ofspecimen collection, process-
ing, transport, and storage), analytical
quality, limitations ofanalytical methods,
and the applicability and specificity ofref-
erence ranges, including the range of nor-
mal intraindividual variability. Issues of
specimen integrity may be particularly rele-
vant when specimens are collected and
processed at one site and then transported
to a geographically distant reference labora-
tory, as in nearly all the cases described in
"Unexplained Chemical-associated Illnesses
and Measures of Heme Synthesis." Speci-
men integrity is a particular concern in
enzyme activity assays. There is the risk of
obtaining falsely low measurements of
enzyme activity because of the potential
lability of enzymes after removal from the
body. Because ofthese risks, an abnormal
test result generally should be confirmed by
analysis ofa second specimen. The need to
repeat a test, of course, must be tempered
by the degree of support for a diagnosis
from other clinical and laboratory data,
and by the feasibility of repeating the test
(i.e., the appropriate clinical circumstances
should still be present).
ReferenceRanges
In addition to considering methodologic
limitations, the interpretation ofany labo-
ratory test should consider potential limita-
tions of the test reference range. First,
reference ranges usually do not include all
possible values for normal people (184).
It is common laboratory practice to define
a reference range as the mean ± 2 SD,
based on the distribution of test results in
an ostensibly normal reference sample;
therefore, it is expected that 5% ofnormal
individuals, and possibly more ifthe distri-
bution is skewed, will have low or high
outlying values. Second, the range ofpossi-
ble test values may overlap for normal and
affected individuals, and many tests might
be more appropriately characterized as hav-
ing an inconclusive range or a continuum
between normal and diagnostic ranges,
rather than simply being dichotomized
(185-187). Third, the usual ranges oftest
values for normal individuals and for indi-
viduals with a given disease may differ so
substantially that intermediately abnormal
values might be regarded as nondiagnostic
for that disease.
It is particularly important to recognize
that there can be considerable normal
intraindividual variation in physiologic
tests (183); often for specific tests either
this has not been characterized or the
degree ofexpected variability has not been
made known to the clinician. Any such
variation, however, can limit the clinician's
ability to interpret a test result confidently
as abnormal when an individual's single
result is outside the reference range by an
amount that is small relative to expected
intraindividual variability on that test. One
study, for example, reported a 3-fold differ-
ence between the highest and lowest total
porphyrin measurements in 24-hr urine
specimens (normally comprised mostly of
coproporphyrin) collected over 7 consecu-
tive days from the same person; all values
were normal except one that exceeded the
value reported for the upper limit ofnormal
by about 25% (131).
Finally, because a reference range may
be unique to the assay method and the lab-
oratory performing the test, test results
should be interpreted relative to the labora-
tory-specific reference range and/or, ifsuf-
ficient general clinical experience exists,
against accepted absolute reference stan-
dards. However, a reference range mayhave
limited representativeness for test subjects,
even when derived from a large sample of
normal individuals, if test subjects differ
from the reference sample in terms of the
circumstances affecting specimen integrity
or in terms ofpotentially confounding per-
sonal factors. For example, the study of
PBB-exposed Michigan farm families (see
"Environmental Chemicals and Effects on
Measures") found total urine porphyrins
were significantly higher on average than
those in the Dutch reference sample, but
they were no different than those in a
contemporary control group ofWisconsin
farm families (131).
EnzymeActivityMeasurements
The diagnostic value of activity measure-
ments for heme-synthesis enzymes depends
on the presence or absence of symptoms
and on other clinical and laboratory data,
particularly the level and pattern of any
associated overproduction ofheme precur-
sors. Individuals who are genetically predis-
posed to a porphyria usually will have
deficient activity ofthe associated enzyme,
yet a substantial proportion will never
develop symptoms of a porphyria. There-
fore, identification ofthe genetic trait alone
in a symptomatic patient is not by itself
sufficient evidence of symptom causality.
In addition, reductions in enzyme activity
do not necessarily reflect a genetic trait;
certain exogenous agents such as alcohol or
lead can inhibit or interfere with the activ-
ity or alter the synthesis ofspecific enzymes
in the heme synthesis pathway (11,74).
Conversely, normal enzyme activity mea-
surements can reduce the likelihood,
although they do not completely eliminate
the possibility, that a person has porphyria.
There is typically a substantial degree of
overlap in enzyme activity values for nor-
mal individuals and for individuals with a
porphyria characterized by deficiency in
that enzyme (73,188). Also, some porphy-
rias do not necessarily manifest the associ-
ated enzyme deficiency in erythroid cells,
even though it may be present in other tis-
sues (e.g., variant AIP, when a mutation is
in or near exon 1 of the PBG deaminase
gene and affects only the nonerythroid
enzyme) (10).
The measurement of specific heme-
synthesis enzyme activities is commonly
considered a second-line test in the evalua-
tion ofporphyrias (189). Enzyme activity
measurements are most often used for iden-
tifying a genetic trait for porphyria in fam-
ily members ofa person with diagnosed or
suspected porphyria to identify individuals
who should be counseled on the need to
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minimize or avoid exposure to factors
known to precipitate porphyria, even
though they may have been asymptomatic
to date (7,188,190,191). Enzyme activity
measurements also can be useful when a
symptomatic person is diagnosed as having
a porphyria ofsome type-based on symp-
tom pattern and a substantial increase in
excretion of heme precursor(s)-but the
pattern ofheme-precursor excretion does
not allow differentiation of the specific
type ofporphyria; proofofdeficient activ-
ity for a specific heme-synthesis enzyme
can facilitate determination ofthe specific
porphyria. Measurements of enzyme
activity otherwise have limited utility in
the evaluation of suspected porphyria in
symptomatic individuals.
CoprovorDhvrinozen OxidaseActivity
Decreased Copro-O activity is the most
frequently identified enzyme finding, and
in many cases is the sole basis for diagnos-
ing a disturbance ofheme synthesis in the
above-mentioned cases of unexplained
chemical-associated illnesses with reportedly
abnormal measures ofheme synthesis (see
"Unexplained Chemical-associated Illnesses
and Measures ofHeme Synthesis").
The assay for Copro-O activity is the
subject of some controversy. At present,
only one laboratory offers a Copro-O activ-
ity assay on a commercial basis. That assay
is performed by the incubation ofALA
substrate with a lysed peripheral blood cell
specimen, followed by analysis ofthe por-
phyrins formed; a low yield ofprotopor-
phyrin and a normal or increased yield of
coproporphyrins indicate a deficiency of
Copro-O (183). The commercial assay,
therefore, uses coproporphyrinogen synthe-
sized enzymatically in situ from ALA added
to the incubate. In contrast, research labo-
ratories that perform Copro-O activity
assays in peripheral blood cells do so in iso-
lated leukocyte or lymphocyte fractions,
using externally synthesized coproporphy-
rinogen as specific substrate (16,192-194).
It is widely believed that heme synthesis
in humans is confined to nucleated cells
and that Copro-O is a mitochondrial
enzyme. However, there is little published
information that addresses the relative
degrees of Copro-O activity in reticulo-
cytes, mature erythrocytes, and leukocytes
(16,195,196). Heme synthesis in periph-
eral blood cells is expected to occur only in
leukocytes and perhaps in reticulocytes,
and not in mature erythrocytes, which lack
nuclei and mitochondria and which consti-
tute about 99% ofperipheral blood cells.
Mitochondria are present in nucleated
blood cells but are not normally present in
mature erythrocytes. Developers of the
lysed-blood assay maintain, however, that
circulating erythrocytes can transform 10 to
40% ofavailable coproporphyrinogen III to
protoporphyrinogen during 3-hr incuba-
tions, with reticulocytes having at least
twice as much Copro-O activity as older
erythrocytes, and with overall erythrocyte
activity far exceeding that seen in lympho-
cytes (RD Ellefson, personal communica-
tion). The subcellular distribution of the
reported Copro-O activity in erythrocytes is
undear; remnants ofmitochondria are one
speculated possibility.
It is generally agreed that because the
percentage of reticulocytes varies among
normal persons and can change dramati-
cally in a number ofdisease states, interpre-
tation of test values from the lysed-blood
assay should at least be adjusted for the
reticulocyte count (183). It is also agreed
that regardless of the technique used to
assay activity, Copro-O is a particularly
labile enzyme after removal from the body.
Vigorous specimen processing or failure to
properly maintain the specimen during
transport or storage can cause enzyme
damage and produce falsely low (i.e., false
positive) test results (183).
Evaluating the Symptomatic
Patient in Whom Porphyria
Is Suspected
The most important first step toward
diagnosing or ruling out porphyria in a
symptomatic patient is for the clinician to
maintain a high index of suspicion for a
possible diagnosis ofporphyria, whether
symptoms are classic for a porphyria or are
vague or unexplained. The conclusive diag-
nosis ofa porphyria should be based on a
systematic approach incorporating medical
history, physical examination, and biochem-
ical data, and including genetic evaluation if
necessary. Certain symptom patterns, physi-
cal findings, and elements ofthe exposure
history may raise the degree ofsuspicion for
porphyria; however, the lack ofsupporting
information from these sources cannot
exclude a diagnosis ofporphyria. Therefore,
the systematic approach to evaluating a
symptomatic patient with suspected por-
phyria must include laboratory evaluation
(see also "Biochemistry ofPorphyrias").
LaboratoryEvaluation-
Diagnosis ofPorphyria
The nature and pattern of a patient's
symptoms and physical signs may provide
some guidance in the selection oftests for
evaluating the symptomatic patient with
suspected porphyria. However, the neuro-
logic and cutaneous manifestations ofpor-
phyrias can be nonspecific or atypical and
caution is necessary to avoid being overly
focused on the basis ofclinical appearance
in initial test selection. Reviewers make
slightly different recommendations regard-
ing the appropriate panel offirst-line tests
for the evaluation ofsuspected porphyria.
The most common recommendation-
when symptoms suggest possible neurologic
manifestation(s) ofan acute porphyria-is
for the measurement ofPBG with or with-
out ALA in urine (46,52,54,189). Most
reviewers also recommend quantification of
total or individual porphyrins in urine and,
routinely or supplementally, in stool-par-
ticularly when symptoms or signs suggest
possible cutaneous manifestations of por-
phyria. Measurement ofprotoporphyrin in
blood is often recommended, depending
on the degree ofsuspicion for erythropoietic
protoporphyria. Anderson (10) alterna-
tively recommends measurement of total
plasma porphyrins, plus urine PBG and
ALA, to determine the presence or absence
of porphyria. A blood lead level, with or
without a ZPP level, should also be consid-
ered because ofthe similarity ofsymptoms
in lead poisoning and porphyrias with
neurologic manifestations.
It is generally less difficult to determine
whether a patient has porphyria than it is
to differentiate which specific type ofpor-
phyria is present. The presence or absence
of increases in urinary ALA and PBG and
the relative increases in the individual por-
phyrins are particularly helpful in diagno-
sis. The nature and pattern of reported
symptoms can assist in differentiation. The
cited general references and review articles
(1-10,46,52,54,189) provide information
regarding the patterns oflaboratory abnor-
malities to consider in attempting to differ-
entiate the specific type ofporphyria in the
patient who has laboratory and clinical evi-
dence consistent with a porphyria. We will
not discuss further this level ofdifferential
diagnosis; we will focus on preliminary
screening steps in the diagnostic evaluation
ofa possible porphyria.
LaboratoryEvaluation-
ExcludingPorphyria
asthe Cause o Symptoms
As discussed in"Biochemistry ofPorphyrias,"
when a porphyria (or another clinically
important disturbance ofheme synthesis,
e.g., lead intoxication) of any recognized
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type is symptomatic, it is almost always
accompanied by substantial overproduction
and increased excretion ofheme precursors,
typically at least several-fold greater than
the value reported for the upper limit of
normal. One possible but infrequent excep-
tion occurs after a patient with acute por-
phyria develops a neurologic deficit that
becomes permanent while the porphyria
is otherwise in remission; biochemical
parameters may return to normal ranges.
Conversely, in a patient who is cur-
rently or recently symptomatic and who is
suspected to have a porphyria, it is not
probable that the patient's symptoms are
attributable to a porphyria of any type
unless a measurement on at least one ofthe
following tests is greater than twice the
value reported for the upper limit ofnor-
mal: ALA, PBG, uroporphyrin, or copro-
porphyrin in urine; blood total porphyrins;
or fecal coproporphyrin (see "Biochemistry
ofPorphyrias") (90,189). Ablood lead level
should be checked to determine the possi-
bility oflead intoxication iflead exposure
is possible, ifexcretion ofcoproporphyrin
or ALA is increased, or ifblood porphyrins
(e.g., ZPP) are increased. Ifa person is cur-
rently or recently symptomatic and has
reduced activity ofa specific heme-synthe-
sis enzyme, but laboratory testing does not
reveal overproduction ofheme precursors
in a pattern and levels consistent with the
porphyria associated with deficiency ofthat
enzyme, then the reduction in measured
enzyme activity has no probable causative
relationship to the person's symptoms.
Satisfaction of these 2-fold-threshold
screening criteria does not necessarily estab-
lish a diagnosis ofporphyria. Depending on
the degree and pattern ofabnormalities on
these tests, additional testing may be neces-
sary to establish or exclude a diagnosis of
porphyria. It is possible that an individual
could have an abnormal heme-precursor
measurement with this degree of abnor-
mality as a consequence ofsomething other
than porphyria (or lead intoxication).
Other medical conditions can cause sec-
ondary porphyrinuria of this magnitude.
Blood porphyrins can also be increased
by this magnitude in conditions other
than porphyria; for example, iron defi-
ciency commonly produces an increase in
blood ZPP.
Conversely, failure to satisfy these
2-fold threshold-screening criteria does not
necessarily exclude a diagnosis of por-
phyria. Heme-precursor measurements in
the range of one to two times the value
reported for the upper limit of normal
should not be interpreted as normal but
rather as indeterminate or nondiagnostic.
The timing ofsample collection relative to
the occurrence of symptoms is critical.
When a patient with suspected porphyria is
not currently or recently symptomatic, the
levels ofheme-precursor excretion are gen-
erally lower and can even normalize with
time (i.e., within days to weeks). If a
patient's last symptoms occurred remotely
in the time relative to specimen collection,
it may be necessary to repeat the tests dur-
ing or as soon as possible after future symp-
toms. In view ofexpected interindividual
variations and the potential processing and
analytic limitations oflaboratory tests, par-
ticularly at the low range of abnormality,
mildly abnormal levels ofheme-precursor
excretion generally should be repeated
before utilizing them as justification for
furtherdiagnostic assessment.
SecondaryPorphyrinurias
Indeterminate or nondiagnostic levels of
porphyrin excretion might represent a sec-
ondary porphyrinuria. With the note-
worthy exception oflead poisoning, the
porphyrin excess in secondary porphyrin-
uria has no recognized clinically detectable
consequences of its own. Medical condi-
tions that appear to have only secondary
effects on the heme synthesis pathway
are appropriately evaluated, with atten-
tion focused on the primary condition.
Similarly, when chemical exposures are sus-
pected as the cause ofa patient's symptoms
or medical condition, the exposure rela-
tionship can be characterized more speci-
fically by exposure assessment or by
quantification of the suspected chemical
(or its metabolite) in blood or urine than
by measurement ofheme precursors. Lead
poisoning, for example, is probably the
most commonly recognized condition that
can result from a chemical exposure and
that is accompanied by abnormal measures
ofheme synthesis. However, even though
these measures provide sensitive indicators
oflead exposure and effect, the blood lead
level is a more sensitive and more specific
test for the diagnosis and management of
lead poisoning.
Exposure Relationships
If it is ultimately determined that a
symptomatic patient has a specific por-
phyria or another clinically important dis-
turbance of heme synthesis (e.g., lead
intoxication) and ifthe possibility ofexpo-
sure relationship or work relationship is at
issue, then the exposure history and any
independently available exposure data
should be reviewed to assess the likelihood
that an exogenous chemical(s) might have
triggered or caused the diagnosed condi-
tion. The potential complexity ofthe expo-
sure assessment process is beyond the scope
ofthis review. Exogenous agents that are
known or suspected to cause or to trigger
porphyria are discussed above. Given that
there has been onlylimited systematic study
ofpotentially porphyrinogenic chemicals in
humans, however, consideration ofpossible
exposure relationships should not be con-
fined to chemicals known or suspected to
affect heme synthesis.
Conclusions
There is little question that individuals
who are genetically predisposed to a por-
phyria can have clinical manifestations of
porphyria triggered by exogenous chemicals.
Most ofthe experience with such chemical
triggering ofporphyria has involved alco-
hol consumption and pharmacological
doses ofdrugs. However, other chemical
exposures have also been reported to trig-
ger porphyrias with neurologic manifesta-
tions as well as those with only cutaneous
manifestation-PCT in particular.
It is also clear that certain exogenous
chemical exposures can actually cause
porphyria in the absence of genetic pre-
disposition. This is demonstrated most con-
vincingly by the Turkish epidemic of PCT
caused by HCB intoxication. Other chemi-
cals have also been linked to cases ofporphy-
ria in humans; the reported cases, however,
have been infrequent, have all involved
PCT, and have generally been linked to
chronic industrial exposures, industrial acci-
dents, or environmental exposures that
were much higher than normally encoun-
tered. Chemical exposures have not been
established as a cause (i.e., not just a trigger
in the presence ofgenetic predisposition) of
porphyrias with primarily neurologic mani-
festations, although lead intoxication is
noteworthy as apossible exception.
There is no doubt that lead absorption
can cause substantial disturbance ofheme
synthesis. Lead intoxication has prominent
manifestations as well as biochemical abnor-
malities that mimic the manifestations of
the neurologic porphyrias. It is not known
to what degree the neurologic manifesta-
tions oflead poisoning might be attribut-
able (ifat all) to the associated disturbance
in heme synthesis, apart from the directly
neurotoxic properties oflead, but there is
evidence the disturbed heme-forming
system mayhave some contributing role.
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It must be acknowledged that there
have been only alimited number ofsystem-
atic attempts to identify porphyria or even
subclinical porphyrinuria in chemically
exposed humans, and that a large number
ofchemicals have been identified as por-
phyrinogenic in experimental animals-
albeit with doses much greater than the
usual range ofhuman experience. In some
cases, these effects result from inhibition of
or interference with specific enzymes in the
heme synthesis pathway; however, some of
these effects can be produced by mecha-
nisms that do not involve an abnormality
in the heme-forming system. Regardless of
the causative mechanism, these chemical-
related changes have potential utility as
biological indicators ofchemical exposures
that might have significant pathologic
effects. There is a need for further research,
including trial field applications, ofsuch
porphyrin biomarkers.
Clinicians should maintain a reasonable
degree ofsuspicion for the possibility ofa
disturbance in heme synthesis underlying
any unexplained syndrome characterized
by nonspecific symptoms if even mildly
reminiscent ofporphyria, whether or not
environmental chemical exposures are sus-
pected as causative or contributing agents.
However, heme-precursor measurements
obtained when a patient is symptomatic
should be interpreted cautiously and/or
repeated ifnot substantially elevated (i.e.,
atleast 2-fold greater) relative to the respec-
tive value reported for the upper limit
ofnormal.
With the noteworthy exceptions oflead
intoxication and the porphyrias in clini-
cally active states, the porphyrin excess
associated with porphyrinurias has no
known clinically detectable consequences
ofits own. Symptoms associated with such
secondary porphyrinurias are attributed by
most reviewers to the condition or agent
causing the porphyrinuria or to an unre-
lated cause and not to a disturbance in
heme synthesis. Such porphyrinuria may
be relevant as a nonspecific laboratory indi-
cator ofsome other operative pathophysio-
logic mechanism, much as an elevated
sedimentation rate can provide contribu-
tory but nonspecific evidence ofdisease;
however, it is most appropriate for further
diagnostic attention to focus on the pri-
mary condition or exposure ofconcern,
not necessarily on a mild disturbance of
heme synthesis.
Avariety ofchemical-associated illnesses
with unknown causative mechanisms,
notablyMCS syndrome, havebeen reported
in association with abnormal results of
porphyria-related tests. It is hypothesized
that these test values reflect pathophysio-
logic disturbances ofheme synthesis that
are directly involved in the manifestation
of those illnesses. Proponents of these
hypotheses point out that many MCS
symptoms resemble the neurologic and
cutaneous manifestations of porphyrias.
Yet, cutaneous symptoms are usually not a
major feature of MCS syndrome, and
when present, they differ substantially
from the cutaneous manifestations ofthe
inherited and acquired porphyrias. The
noncutaneous symptoms of MCS syn-
drome are much less intense and less
discretely episodic than the common neu-
rologic manifestations ofporphyrias. The
clinical course ofporphyrias with neuro-
logic manifestations can, as with MCS syn-
drome, occur in a chronic or indolent
pattern, and does not occur exclusively
as acute symptom attacks separated by
symptom-free intervals; however, in the
neurologic porphyrias, in contrast to MCS
syndrome, the chronic pattern occurs
much less frequently than the pattern of
acute symptom attacks.
Proponents ofporphyric hypotheses for
MCS syndrome point out another similar-
ity with the porphyrias-the propensity for
symptoms to be caused or triggered by
exogenous chemical exposures. However,
the very low levels of exposure to which
MCS patients are characteristically sensitive
are much lower than the pharmacological
doses ofdrugs that are known to trigger
neurologic symptoms in genetically predis-
posed individuals. These levels are also
much lower than the chemical exposures
reported to date in association with PCT or
subclinical porphyrinurias in humans,
where situations generally have involved
chronic industrial exposures, industrial acci-
dents, or environmental exposures that
were much higher than normally encoun-
tered, andwith the exception oflead intoxi-
cation, have not been reported to involve
low-level environmental exposures.
It is conceptually difficult to reconcile
why MCS syndrome, ifmediated substan-
tially through a disturbance in heme syn-
thesis, would have a markedly greater
degree ofchemical intolerance and greater
frequency ofchronic functional limitations
than recognized forms ofprophyria but
would never manifest symptoms or signs as
severe as can occur with porphyrias, and
would have markedly lower or even absent
elevations ofheme-precursor excretion
when symptomatic compared to porphyria
patients when symptomatic. One contention
is that circumscribed disturbances ofheme
synthesis (i.e., limited to a small number of
cells) can cause symptoms without produc-
ing measurable or substantial increases in
heme precursors and that heme-synthesis
enzyme measurements, therefore, are the
more critical, if not the only necessary,
diagnostic measure. Although it is well rec-
ognized that heme synthesis can be dispro-
portionately affected in different organ
systems with any one type ofporphyria, it
is contrary to other clinical evidence to
date (with rare exceptions) that a distur-
bance ofheme synthesis is so profound as
to produce symptoms without also produc-
ing substantial elevations ofheme precur-
sors. Similarly, there is no other evidence
to date that a heme-synthesis enzyme
with low activity, particularly when mar-
ginal activity values are overinterpreted as
low, can be linked to symptoms without
an accompanying substantial increase in
heme precursors.
It is sometimes contended in individual
cases that the timing ofspecimen collection
was not sufficiently dose in time to a symp-
tom episode to depict the full degree of
heme-precursor abnormalities associated
with that individual's symptoms. Although
the biochemical abnormalities ofsome por-
phyrias may return to normal ranges during
periods ofclinical remission, such normal-
ization generally requires at least several
days or weeks, ifit occurs at all. Given the
typical frequency ofsymptom episodes in
individuals with MCS syndrome, and ifa
disturbance ofheme synthesis is an opera-
tive pathophysiologic mechanism, the tim-
ing ofspecimen collection should not be
an issue.
To date, the efforts to relate MCS
syndrome and other unexplained chemical-
associated illnesses to disturbances ofheme
synthesis have all involved selected case
series with no consistent or stated case defi-
nitions, using only laboratory reference
ranges for comparisons, and with little or
no attention to the methodologic and
interpretive limitations of measures of
heme synthesis. Based on the limited exist-
ing data, it is reasonable at least to consider
the possibility that there might be a higher
than previously recognized prevalence of
abnormalities in measures ofheme synthe-
sis among patients with MCS syndrome.
However, to date there is no convincing
evidence that there is-or is not-any
such increased prevalence of abnormal
measures ofheme synthesis associated with
MCS syndrome. Given the current paucity
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of evidence in favor of disturbances of
heme synthesis being operative in MCS
syndrome and other unexplained chemical-
associated illnesses, and unless supportive
evidence can be provided by well designed
and controlled studies, the proposed
relationships with disturbances ofheme
synthesis should, at most, be considered
speculative and unestablished. In cases
involving these otherwise unexplained ill-
nesses, and when there is no demonstrable
substantial accumulation or increased
excretion ofheme precursors, it is premature
or unfounded either to apply a diagnosis of
porphyria (or any less defined pathologic
disturbance ofheme synthesis) or to use
such diagnoses as specific justification for
lifestyle alterations or therapeutic interven-
tions; porphyria-specific interventions,
such as intravenous hematin, should not be
recommended in such instances.
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